ERS Genomics and Cellular Engineering Technologies enter CRISPR/Cas9 license agreement
License allows Cellular Engineering Technologies to develop, manufacture and commercialize next generation stem cell lines using CRISPR/Cas9 technology
Avacta announces first patient dosed in AVA6000 Pro-Doxorubicin Phase I clinical trial
Cambridge and Wetherby... Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the first patient has been dosed in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin.
FUJIFILM Irvine Scientific becomes sole worldwide distributor of Presagen’s Life Whisperer
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection.
Dotmatics to deliver the foundation for Croda’s R&D digital programme: artificial intelligence and data mining
Bishop’s Stortford, UK... Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has been selected by Croda International Plc to implement its Research and Development (R&D) digital programme. Croda is the name behind the high-performance ingredients…
ERS Genomics and Japan SLC sign CRISPR/Cas9 licence agreement
Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models.
Orbit Discovery announces $7.6 million funding to accelerate growth in peptide discovery business
Oxford...Orbit Discovery Ltd, a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million (USD) in funding.
Dotmatics announces support for AWS for Health initiative
Dotmatics, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, announced support for the AWS for Health initiative from Amazon Web Services (AWS) to improve laboratory efficiency and accelerate the pace of scientific innovation by facilitating more rapid data access, analysis and…
Mologic to become a ‘social enterprise’ after acquisition by social impact funders and investors
A group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation, is today announcing the launch of Global Access Health (GAH), a social enterprise that will seek to expand access to affordable state-of-the-art medical technology through decentralized research, development, and manufacturing in and for the…
H.E.L Group strengthens operations in North America
London, UK, 15 July 2021: H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimisation, safety and scale-up, today announced that it has expanded its operations in North America, with the establishment of a West Coast hub in California, and a Central Region hub in Missouri.
Bio-Rad launches its Reliance SARS-CoV-2/FluA/FluB RT-PCR assay kit in Europe
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements.
Avacta’s Diagnostic Division achieves ISO 13485 certification
Cambridge and Wetherby, UK, 14 July 2021: Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that Avacta Life Sciences’ diagnostics division has achieved ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for…
Gyros Protein Technologies and Cygnus Technologies expand collaboration
Uppsala, Sweden, 07 July 2021: Gyros Protein Technologies (part of Mesa Labs’ Biopharmaceutical Development Division), a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the next phase of its on-going collaboration with Cygnus Technologies, a Maravai LifeSciences company, and the introduction of a new HEK 293 HCP…
Birmingham University and Nonacus partner to develop urine test for bladder cancer
Birmingham, UK, 01 July 2021: Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, and the University of Birmingham have partnered to develop a non-invasive test for bladder cancer.
ERS Genomics and Nippon Gene sign CRISPR/Cas9 licence agreement
Dublin, Ireland and Tokyo, Japan, 01 July 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and Nippon Gene Co Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive licence…
FairJourney Biologics introduces 'THE ANTIBODY SERIES' Conference
FairJourney Biologics SA (FJB), leaders in the discovery and optimization of antibodies, today announced the launch of the “THE ANTIBODY SERIES” - a one-day conference bringing together top experts in the antibody field to explore the latest innovation within antibody drug discovery.
CrestOptics selected by Akoya Biosciences for spatial biology collaboration
Rome, IT, 29 June 2021: CrestOptics SpA, a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, today announced that it has been selected by Akoya Biosciences Inc, (Nasdaq: AKYA) The Spatial Biology Company®, as a premier microscope provider to jointly develop new spatial biology and spatial phenotyping applications.
Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test detects Delta variant
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests that are…
Orbit Discovery appoints Dr Neil Butt as Chief Executive Officer
Oxford, UK, June 29, 2021: Orbit Discovery Ltd, a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil Butt as Chief Executive Officer.
Optibrium publishes major peer-reviewed study on AI applications to global pharma data
Published in AI Letters, study collaborators Optibrium, Takeda and Intellegens demonstrated the application of deep learning imputation to a global pharma dataset, offering new insights into drug discovery data that transform how complex data can be used to identify opportunities for new drugs and streamline the drug discovery process.
LegoChem Biosciences and Iksuda Therapeutics expand licence agreement for development of antibody-drug conjugates
Newcastle, UK, 22 June, 2021: Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and Licence Agreement with LegoChem Biosciences, Inc. (“LCB”) to explore additional ADC programmes which leverage LCB’s proprietary ADC platform technology.
Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test distribution agreement
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Calibre Scientific Inc, a global provider of life science products, for Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test for professional use in the UK…
The Native Antigen Company wins ‘The Best COVID-19 Responder’ at OBN 2020 Awards
Oxford, UK: The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases, won ‘The Best COVID-19 Responder’ at OBN 2020 Awards. The award recognises the Company’s outstanding contribution to the fight against COVID-19.
Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001
Brighton, UK, 14 June 2021: Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis (CF) therapy, ETD001. The first-in-man safety study is being…
Avacta announces registration of its AffiDX SARS-CoV-2 antigen lateral flow test in EU
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has received notice of registration of its AffiDX® SARS-CoV-2 antigen lateral flow test in the EU allowing the Company to place the product on the market in all 27 countries of the EU for professional use.
Bio-Rad introduces three StarBright dyes for flow cytometry
The StarBright Violet 570, StarBright Violet 670, and StarBright Violet 710 dyes offer precise excitation and emission spectra for improved brightness and resolution.